Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ResMed Inc. is a holding company. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. It also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. The Company’s segments include Sleep and Respiratory Care and SaaS. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care to improve patient outcomes.

  • Revenue in USD (TTM)4.81bn
  • Net income in USD1.11bn
  • Incorporated1994
  • Employees9.98k
  • Location
    Resmed Inc9001 Spectrum Center BlvdSAN DIEGO 92123-1438United StatesUSA
  • Phone+1 (858) 746-2400
  • Fax+1 (302) 636-5454
  • Websitehttps://www.resmed.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cooper Companies Inc3.80bn359.30m20.31bn15.00k56.802.5627.605.341.801.8019.0239.800.31961.705.56253,606.703.0210.063.2911.3466.3665.549.4529.001.185.460.24930.34698.617.24-23.74-3.6615.180.00
Zimmer Biomet Holdings Inc7.60bn1.08bn21.89bn18.00k20.941.7710.632.885.255.2536.8762.000.35380.91365.38421,972.205.052.215.822.5271.7871.2514.287.280.69877.520.342538.906.55-1.40252.86--9.440.00
Steris PLC5.12bn602.62m21.96bn18.18k36.663.3319.834.296.084.3851.6266.800.47583.865.49281,655.405.625.196.105.6843.0143.6411.8110.971.558.290.252836.5613.2813.06-1.0712.6713.698.83
Waters Corp2.91bn622.64m22.91bn7.90k36.8114.2928.127.8810.4810.4848.8927.000.6452.204.47367,740.1013.8219.7716.7225.2959.7358.4521.4323.381.3810.110.53250.00-0.52294.09-9.261.534.72--
Illumina Inc4.39bn-1.58bn23.41bn10.59k--11.05--5.33-10.00-10.0027.6113.360.54412.666.17414,542.00-19.63-6.20-23.16-7.2863.9466.39-36.08-15.481.8538.440.4834---1.756.2173.64---7.91--
West Pharmaceutical Services Inc.2.88bn499.60m23.73bn10.60k48.558.6337.428.256.756.7538.8637.960.77434.505.51271,358.5013.0215.6115.1618.6534.8738.0616.8118.472.23--0.069510.692.1811.432.2823.7628.166.20
DexCom Inc3.95bn680.80m29.04bn9.60k45.3814.6732.517.341.641.649.525.070.61072.764.42411,875.0010.518.3014.2810.5062.1065.9017.2214.142.12--0.55790.0024.4928.5658.70--28.66--
IDEXX Laboratories, Inc.3.84bn866.24m34.89bn11.00k41.1121.6035.179.0810.3610.3646.0019.721.193.857.14349,528.8026.9128.0038.8643.4960.7258.7422.5321.351.0359.100.35070.008.7210.5924.4417.391.68--
Resmed Inc4.81bn1.11bn36.29bn9.98k32.776.9828.147.557.547.5432.5935.390.68862.176.08481,711.9015.9414.2418.1116.5357.6756.8523.1520.351.9144.710.115432.6210.9512.4413.7519.988.235.34
Veeva Systems Inc2.57bn615.26m38.30bn7.17k61.377.3858.7614.883.853.8515.6932.040.4453--6.27358,846.8010.6511.9712.9715.3673.3572.0023.9123.74----0.000.009.6822.357.7918.0021.68--
Agilent Technologies Inc6.50bn1.41bn38.41bn17.40k27.806.5123.105.914.814.8122.1420.530.59962.875.06358,950.3013.0411.0016.1313.2554.7553.2921.7518.011.3755.860.331921.46-0.2196.82-1.127.3910.988.86
GE HealthCare Technologies Inc19.56bn1.68bn38.80bn51.00k23.264.6616.771.983.653.6542.6318.200.59065.404.41383,490.205.22--6.97--41.33--8.84--0.9825.670.5478--6.60---26.82------
Edwards Lifesciences Corp5.62bn1.43bn38.81bn19.80k27.794.0724.856.902.376.939.3216.180.50321.127.72283,904.0012.7616.6314.9819.1278.6376.7125.3524.842.89--0.05850.0011.5610.03-7.8513.701.96--
Cencora Inc293.96bn1.51bn49.02bn42.00k33.1562.3118.600.16687.517.511,467.703.994.5315.5912.44--2.341.1211.514.833.353.250.51680.25560.529119.370.84865.3812.1210.36-13.5313.029.454.98
Data as of Nov 13 2024. Currency figures normalised to Resmed Inc's reporting currency: US Dollar USD

Institutional shareholders

31.76%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Jun 202417.26m11.75%
BlackRock Fund Advisorsas of 30 Jun 20248.71m5.93%
SSgA Funds Management, Inc.as of 30 Jun 20246.14m4.18%
Walter Scott & Partners Ltd.as of 30 Jun 20244.71m3.21%
Geode Capital Management LLCas of 30 Jun 20243.48m2.37%
Morgan Stanley & Co. LLCas of 30 Jun 20242.08m1.42%
Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 20241.35m0.92%
BlackRock Advisors (UK) Ltd.as of 30 Jun 20241.02m0.70%
Invesco Advisers, Inc.as of 30 Jun 2024998.30k0.68%
Charles Schwab Investment Management, Inc.as of 30 Jun 2024910.06k0.62%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.